MX2011009225A - Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. - Google Patents
Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.Info
- Publication number
- MX2011009225A MX2011009225A MX2011009225A MX2011009225A MX2011009225A MX 2011009225 A MX2011009225 A MX 2011009225A MX 2011009225 A MX2011009225 A MX 2011009225A MX 2011009225 A MX2011009225 A MX 2011009225A MX 2011009225 A MX2011009225 A MX 2011009225A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- skin
- disitertide
- therapeutic treatment
- tumors
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 60
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 22
- 206010029098 Neoplasm skin Diseases 0.000 title claims abstract description 18
- 230000000069 prophylactic effect Effects 0.000 title description 5
- IUYPEUHIWDMJLM-SWHDLQTQSA-N (2s)-4-amino-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino Chemical group C1=CC=C2C(C[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 IUYPEUHIWDMJLM-SWHDLQTQSA-N 0.000 claims abstract description 54
- 229950009903 disitertide Drugs 0.000 claims abstract description 54
- 230000003449 preventive effect Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 26
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 17
- 201000009030 Carcinoma Diseases 0.000 claims description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 16
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 10
- 208000009621 actinic keratosis Diseases 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000010153 skin papilloma Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 22
- 208000003154 papilloma Diseases 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 16
- 208000005623 Carcinogenesis Diseases 0.000 description 15
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 15
- 230000036952 cancer formation Effects 0.000 description 15
- 231100000504 carcinogenesis Toxicity 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 201000000849 skin cancer Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000010088 skin benign neoplasm Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900694A ES2347627B1 (es) | 2009-03-06 | 2009-03-06 | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. |
| PCT/ES2010/070121 WO2010100310A1 (es) | 2009-03-06 | 2010-03-04 | Péptido para el tratamiento profiláctico o terapéutico de tumores de la piel en estadios iniciales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009225A true MX2011009225A (es) | 2011-10-10 |
Family
ID=42709234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009225A MX2011009225A (es) | 2009-03-06 | 2010-03-04 | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8658599B2 (https=) |
| EP (1) | EP2404611A4 (https=) |
| JP (1) | JP2012519671A (https=) |
| CN (1) | CN102341115A (https=) |
| AR (1) | AR075783A1 (https=) |
| AU (1) | AU2010219857A1 (https=) |
| BR (1) | BRPI1013363A8 (https=) |
| CA (1) | CA2753461A1 (https=) |
| ES (1) | ES2347627B1 (https=) |
| MX (1) | MX2011009225A (https=) |
| RU (1) | RU2011140477A (https=) |
| TW (1) | TW201036625A (https=) |
| WO (1) | WO2010100310A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9353149B2 (en) * | 2013-05-10 | 2016-05-31 | Southern Research Institute | Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity |
| CN110483648A (zh) * | 2019-08-27 | 2019-11-22 | 南京安吉生物科技有限公司 | 一种融合多肽及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| JP5650367B2 (ja) * | 2004-02-27 | 2015-01-07 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
| WO2007048857A1 (es) * | 2005-10-24 | 2007-05-03 | Proyecto De Biomedicina Cima, S.L. | USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE |
| EP2305309A2 (en) * | 2008-06-13 | 2011-04-06 | Proyecto de Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
-
2009
- 2009-03-06 ES ES200900694A patent/ES2347627B1/es not_active Expired - Fee Related
-
2010
- 2010-03-03 AR ARP100100633A patent/AR075783A1/es not_active Application Discontinuation
- 2010-03-04 MX MX2011009225A patent/MX2011009225A/es not_active Application Discontinuation
- 2010-03-04 WO PCT/ES2010/070121 patent/WO2010100310A1/es not_active Ceased
- 2010-03-04 EP EP10748370A patent/EP2404611A4/en not_active Withdrawn
- 2010-03-04 JP JP2011552477A patent/JP2012519671A/ja active Pending
- 2010-03-04 AU AU2010219857A patent/AU2010219857A1/en not_active Abandoned
- 2010-03-04 BR BRPI1013363A patent/BRPI1013363A8/pt not_active IP Right Cessation
- 2010-03-04 CA CA2753461A patent/CA2753461A1/en not_active Abandoned
- 2010-03-04 RU RU2011140477/10A patent/RU2011140477A/ru not_active Application Discontinuation
- 2010-03-04 US US13/255,059 patent/US8658599B2/en not_active Expired - Fee Related
- 2010-03-04 CN CN2010800105516A patent/CN102341115A/zh active Pending
- 2010-03-05 TW TW099106502A patent/TW201036625A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2347627B1 (es) | 2011-10-10 |
| JP2012519671A (ja) | 2012-08-30 |
| ES2347627A1 (es) | 2010-11-02 |
| RU2011140477A (ru) | 2013-04-27 |
| BRPI1013363A2 (pt) | 2016-03-29 |
| AU2010219857A1 (en) | 2011-10-06 |
| BRPI1013363A8 (pt) | 2016-07-19 |
| EP2404611A1 (en) | 2012-01-11 |
| CN102341115A (zh) | 2012-02-01 |
| US8658599B2 (en) | 2014-02-25 |
| US20120065144A1 (en) | 2012-03-15 |
| CA2753461A1 (en) | 2010-09-10 |
| TW201036625A (en) | 2010-10-16 |
| EP2404611A4 (en) | 2012-11-21 |
| WO2010100310A1 (es) | 2010-09-10 |
| AR075783A1 (es) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6331298B1 (en) | Wound healing and treatment of fibrotic disorders | |
| WO2009051801A2 (en) | Chemical inhibitors of inhibitors of differentiation | |
| CN1835748A (zh) | 环杷明在治疗牛皮癣和其它皮肤病中的用途 | |
| Lin et al. | Neuregulin-1, a microvascular endothelial-derived protein, protects against myocardial ischemia-reperfusion injury | |
| KR102448705B1 (ko) | 멀티키나아제 억제제, 및 생식관 및 소화관 섬유증에서의 용도 | |
| EP3922251B1 (en) | Cancer immunotheraphy adjuvant | |
| CA2413141C (en) | Peptides with wound healing activity | |
| US20190365858A1 (en) | Methods and compositions for rejuvenating neuromuscular junctions | |
| MX2011009225A (es) | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. | |
| US20130323329A1 (en) | Method Of Using Rhein For Treating Fibrotic Conditions And Tumors | |
| EP3654984B1 (en) | Topical treatment for preventing and mitigating skin cytotoxicity due to therapy with tyrosine kinase inhibitors | |
| KR102003153B1 (ko) | 레졸빈 d2를 유효성분으로 함유하는 피부 염증 치료용 조성물 | |
| JP2022551672A (ja) | 乳癌治療法 | |
| TW201722457A (zh) | 短合成胜肽及其用途 | |
| EP3435990B1 (en) | Stable pharmaceutical compositions for topical administration and uses thereof | |
| López-Saura et al. | Intralesional human recombinant epidermal growth factor for the treatment of advanced diabetic foot ulcer: from proof of concept to confirmation of the efficacy and safety of the procedure | |
| AU2021387517A1 (en) | Pharmaceutical composition for preventing or treating wound or scar, comprising benzbromarone | |
| KR102575465B1 (ko) | 도세탁셀 및 칼키톡신 티올아마이드를 유효성분으로 함유하는 암 전이 억제 및/또는 암 치료 효과 증진용 조성물 | |
| US20240226233A1 (en) | Composition comprising zag-derived peptide for improving scars and keloids | |
| KR102065150B1 (ko) | 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
| RU2359684C1 (ru) | Способ лечения эндометриоза | |
| JP2026046075A (ja) | 細胞性粘菌由来分化誘導因子を含む皮膚線維化疾患の予防または治療のための局所塗布剤 | |
| Fuggetta et al. | Research Article Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study | |
| US20130064878A1 (en) | Wound healing compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: DIGNA BIOTECH, S.L.* |
|
| FA | Abandonment or withdrawal |